$11.06
0.383.6%
Last update: Oct 27, 1:15 AM
ADMA Biologics Inc
ADMANASDAQ
ADMA Biologics (ADMA) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
ADMA Biologics (ADMA) last issued guidance on August 5, 2026 for fiscal year 2026. The company guided revenue in the range of $530M - $560M for the period.
Compared to prior guidance, ADMA Biologics maintained its revenue forecast from a prior range of $530M - $560M.
ADMA Biologics has issued 15 guidance updates between November 9, 2022 and August 5, 2026. During this period, the company raised its outlook 7 times and lowered it 4 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.17 | $0.20 | $0.20 | $0.16 |
| Actual | $0.16 | $0.17 | $0.21 | $0.16 |
| Surprise | -5.88% | -15.0% | +7.50% | 0.00% |
| Revenue | ||||
| Estimate | $126.1M | $140.0M | $139.8M | $130.4M |
| Actual | $124.4M | $114.5M | $139.2M | $134.2M |
| Surprise | -1.34% | -18.2% | -0.46% | +2.96% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.20 | $0.24 | $0.17 | $0.20 |
| Revenue | ||||
| Consensus | $138.5M | $157.1M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $0.16 | $0.17 | -5.88 % |
| Q1 | May 6, 2026 | $0.17 | $0.20 | -15.0 % |
| Q4 | Feb 25, 2026 | $0.22 | $0.20 | 7.50 % |
| Q3 | Nov 5, 2025 | $0.16 | $0.16 | 0.00 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $124.40M | $126.08M | -1.34 % |
| Q1 | May 6, 2026 | $114.49M | $139.97M | -18.2 % |
| Q4 | Feb 25, 2026 | $139.16M | $139.80M | -0.46 % |
| Q3 | Nov 5, 2025 | $134.22M | $130.36M | 2.96 % |
